Spasticity, a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, results from hyper excitability of the stretch reflex. It often causes damage to one or more areas of the central nervous system; therefore, treatment goals should aim to provide symptom relief, ease patient care and decrease caregiver burden, and improve patient function. In order to accomplish these goals, it is imperative that clinicians develop individualized treatment strategies based on shared decision-making, available treatment options, and patient specific factors.
This CMEOCast podcast episode highlights how best to match treatment options with patients, with a specific focus on the safety and efficacy of botulinum toxin as a treatment for patients with spasticity.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Allergan.
Physicians, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Simpson reports that he receives research/grants from Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc. He is on the advisory committee for Allergan; Ipsen Biopharmaceuticals, Inc; Merz Pharma; and Revance Therapeutics, Inc. He is a consultant for Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc. He is on the speakers bureau for Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-100-H01-P.
Call us at 877.CME.PROS (877.263.7767).